Gemini Therapeutics to Participate in the Jefferies Virtual Healthcare Conference
Gemini Therapeutics, a clinical stage precision medicine company focused on age-related macular degeneration (AMD), has announced that CEO Jason Meyenburg will participate in the Jefferies Virtual Healthcare Conference on June 2 at 3:30 PM ET. The event will be webcast live on the company's website, with a replay available for 30 days.
Gemini's lead therapy, GEM103, addresses complement hyperactivity to restore retinal health and is currently in clinical trials for AMD patients. The company also develops a range of therapies, advancing its pipeline of innovative treatments.
- None.
- None.
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the Jefferies Virtual Healthcare Conference on Wednesday, June 2 at 3:30 PM ET.
A live webcast of the event will be available on the "Events & Presentations" page on the Company's website. A replay of the webcast will be archived on the Company's website for 30 days following the presentation.
About Gemini Therapeutics
Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini’s lead candidate, GEM103, is a recombinant form of human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy. The company has generated a rich pipeline including recombinant proteins, gene therapies, and monoclonal antibodies and is advancing a potentiating antibody for CFH, GEM307, into clinical development for treatment of systemic diseases.
For more information, visit www.geminitherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210526005186/en/
FAQ
What is the date and time of the Jefferies Virtual Healthcare Conference for GMTX?
Where can I watch the Jefferies Virtual Healthcare Conference for Gemini Therapeutics?
What is the focus of Gemini Therapeutics' research and development?
What is GEM103 and its purpose in treating AMD?
How is GEM103 currently being tested in clinical trials?
